Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib

• Verfasst von: Sachpekidis, Christos [VerfasserIn]
• Verfasst von: Hassel, Jessica C. [VerfasserIn]
• Verfasst von: Dimitrakopoulou-Strauss, Antonia [VerfasserIn]
• Titel: Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib
• Verf.angabe: Christos Sachpekidis MD, Jessica C. Hassel MD, Antonia Dimitrakopoulou-Strauss MD
• E-Jahr: 2017
• Jahr: September-December 2017
• Umfang: 3 S.
• Fussnoten: DOI lässt sich nicht aufrufen/05.06.2018 ; Gesehen am 05.06.2018
• Titel Quelle: Enthalten in: Hellenic journal of nuclear medicine
• Ort Quelle: Thessaloniki : Hellenic Soc. of Nuclear Medicine, 1998
• Jahr Quelle: 2017
• Band/Heft Quelle: 20(2017), 3 vom: Sept./Dez., Seite 251-253
• DOI: doi:10.1967/s002449910611
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1576022544

Abstract

Combination therapies for the treatment of metastatic melanoma are a matter of debate nowadays. We report on a stage IV metastatic melanoma patient with the BRAF V600 mutation and a large tumor burden initially treated with two cycles of ipilimumab. Due to dramatic disease progression, demonstrated on interim 18F-FDG PET/CT, vemurafenib was added in the patients therapeutical scheme. After completion of the concurrent ipilimumab and vemurafenib administration, a third 18F-FDG PET/CT showed an impressive metabolic remission of the metastatic disease, reflecting the potential role of the modality in treatment response evaluation of melanoma patients receiving combination therapies.